av New regulations in the Food and Drugs Act have lowered the safeguards put in place for the approval of medications in Canada by creating an alternative pathway for their licensing. Amendments are being proposed to define which novel therapeutics will qualify to go through this expedited pathway to being authorized. In their interview with Children’s Health Defense Canada, Deanna McLeod and Judy Stinson give a deep dive into these amendments and their potential impact on the medical rights of Canadians.
